Citadel Advisors
HCAT icon

Citadel Advisors’s Health Catalyst HCAT Stock Holding History

Citadel Advisors’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.9K Buy
+12,500
New +$23.5K ﹤0.01% 12704
2025
Q2 		– Sell
-1,100
Closed -$4.98K – 13526
2025
Q1 		$4.98K Sell
1,100
-8,800
-89% -$46.6K ﹤0.01% 13850
2024
Q4 		$70K Sell
9,900
-4,600
-32% -$36.6K ﹤0.01% 11970
2024
Q3 		$118K Buy
14,500
+8,600
+146% +$62.1K ﹤0.01% 10907
2024
Q2 		$37.7K Sell
5,900
-4,500
-43% -$28.9K ﹤0.01% 12041
2024
Q1 		$78.3K Buy
10,400
+4,800
+86% +$43.8K ﹤0.01% 11683
2023
Q4 		$51.9K Sell
5,600
-15,000
-73% -$123K ﹤0.01% 11749
2023
Q3 		$208K Buy
20,600
+5,200
+34% +$62.1K ﹤0.01% 9824
2023
Q2 		$193K Sell
15,400
-5,700
-27% -$67.9K ﹤0.01% 9954
2023
Q1 		$246K Buy
21,100
+6,600
+46% +$84.1K ﹤0.01% 9792
2022
Q4 		$154K Sell
14,500
-30,600
-68% -$295K ﹤0.01% 10571
2022
Q3 		$437K Buy
+45,100
New +$597K ﹤0.01% 8763
2022
Q1 		– Sell
-15,600
Closed -$618K – 13983
2021
Q4 		$618K Sell
15,600
-5,300
-25% -$242K ﹤0.01% 9150
2021
Q3 		$1.04M Sell
20,900
-17,800
-46% -$971K ﹤0.01% 8041
2021
Q2 		$2.15M Buy
38,700
+20,100
+108% +$1.07M ﹤0.01% 6425
2021
Q1 		$870K Buy
18,600
+11,100
+148% +$538K ﹤0.01% 8441
2020
Q4 		$326K Sell
7,500
-15,600
-68% -$575K ﹤0.01% 8932
2020
Q3 		$845K Buy
23,100
+4,900
+27% +$166K ﹤0.01% 6337
2020
Q2 		$531K Sell
18,200
-1,600
-8% -$44.2K ﹤0.01% 6961
2020
Q1 		$518K Buy
+19,800
New +$605K ﹤0.01% 6406

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's HCAT Position: Q3 2025 in Review

Citadel Advisors sold out of Health Catalyst (HCAT) in Q3 2025, closing a stake of 57,426 shares — an estimated $216K sold.

Citadel Advisors first reported a position in HCAT in Q3 2019 and held it in 23 quarters. The position peaked at $12.4M in Q1 2022. 145 funds tracked by Wall St. Rank hold HCAT as of Q3 2025.

  • Citadel Advisors reported no remaining Health Catalyst position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 57,426 Health Catalyst shares in Q3 2025, an estimated $216K.
  • Citadel Advisors first reported a position in Health Catalyst in Q3 2019 and held it in 23 quarters.
  • Citadel Advisors's Health Catalyst position peaked at $12.4M in Q1 2022.
  • 145 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.